An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
Latest Information Update: 20 Mar 2024
At a glance
- Drugs Pegloprastide (Primary)
- Indications Advanced breast cancer; Carcinoma; Early breast cancer
- Focus Diagnostic use; Registrational
- Sponsors Avelas BioSciences
- 28 Feb 2024 According to a RRD International media release, RRD International name has changed its name RRD Biopharma Development.
- 10 Jun 2021 Status changed from active, no longer recruiting to completed.
- 04 Aug 2020 Primary endpoint has been met. (Determine the accuracy of AVB-620 imaging data to distinguish between malignant and nonmalignant tissues.)